Celsion Corporation Reports Third Quarter 2006 Financial Results.

Revenues Rise 28.6% to $4.1 Million for Quarter. Net Loss Reduced by 51%.

COLUMBIA, Md. -- Celsion Corporation (AMEX: CLN) today announced financial results for its third quarter ended September 30, 2006. The Company reported revenue of $4.1 million for the quarter, compared to $3.2 million for the third quarter of 2005, an increase of 28.6%.

Net loss for the third quarter was $990,000, or $0.09 per basic and diluted share, compared to a net loss of $2.0 million, or $0.18 per basic and diluted share for the comparable quarter in 2005. The 51% reduction in the net loss reflects the strength of the demand for the Prolieve([R]) treatment and a substantial increase in gross margin, up from 31.8% of net sales in third quarter 2005 to 53.9% of net sales in third quarter 2006, due to the commissioning of the new Prolieve disposable catheter kit supplier.

The Company reported revenue for the nine months ended September 30, 2006 of $6.8 million, compared to $8.0 million in the comparable period in 2005. Net loss for the nine months was $6.5 million, or $0.61 per basic and diluted share, compared to $6.6 million, or $0.61 per basic and diluted share in the first nine months of 2005.

Anthony P. Deasey, Celsion's Chief Financial Officer and Interim President and Chief Executive Officer, commented, "We are very pleased with these results. The sales were delivered in the seven weeks since Prolieve was released from recall on August 11. While the sales include building inventory in our distributor, Boston Scientific's, warehouse they also demonstrate the strong market acceptance of Prolieve as a treatment for benign prostatic hyperplasia. We expect this progress to continue and, as a result, we are increasing our guidance for 2006 annual sales from our current estimate of $10 million to $11 million. It is also encouraging to note that the Prolieve profit contribution enabled us to reduce our net cash burn for the third quarter to $900,000 compared to $2.5 million and $4.0 million respectively for the first and second quarters of this year."

"We continue to make good progress in our ThermoDox[TM] liver cancer phase I trial, having recently completed the fourth, 50mg/m, cohort of six patients. Additionally, we have treated, at least once, all three patients in the second cohort of patients in our phase I multiple dose escalation study in recurrent chest wall breast cancer at Duke University Medical Center."

About Celsion: The Prolieve Thermodilatation system is a minimally invasive transurethral microwave system which combines a transurethral microwave thermotherapy device with pressure applied by a balloon catheter.

Prolieve is marketed, in the United States under an exclusive distribution agreement, with Boston Scientific Corporation.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

[TABLE OMITTED]
[TABLE OMITTED]